Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations

Yusuke Daido; Hiroyuki Sugiura; Tatsunori Ishikawa; Taiga Kuroi; Sachiyo Okamoto; Naho Nomura; Taro Masunari; Nobuo Sezaki; Yasuhito Nannya; Seishi Ogawa; Mitsune Tanimoto

doi:10.1159/000533749

Case Reports in Oncology (Sep 2023)

Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations

Yusuke Daido,
Hiroyuki Sugiura,
Tatsunori Ishikawa,
Taiga Kuroi,
Sachiyo Okamoto,
Naho Nomura,
Taro Masunari,
Nobuo Sezaki,
Yasuhito Nannya,
Seishi Ogawa,
Mitsune Tanimoto

Affiliations

Yusuke Daido: Department of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers, Hiroshima, Japan
Hiroyuki Sugiura: Department of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers, Hiroshima, Japan
Tatsunori Ishikawa: Department of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers, Hiroshima, Japan
Taiga Kuroi: Department of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers, Hiroshima, Japan
Sachiyo Okamoto: Department of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers, Hiroshima, Japan
Naho Nomura: Department of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers, Hiroshima, Japan
Taro Masunari: Department of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers, Hiroshima, Japan
Nobuo Sezaki: Department of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers, Hiroshima, Japan
Yasuhito Nannya: Division of Hematopoietic Disease Control, Advanced Clinical Research Center, Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Seishi Ogawa: Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan
Mitsune Tanimoto: Department of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers, Hiroshima, Japan

DOI: https://doi.org/10.1159/000533749
Journal volume & issue: Vol. 16, no. 1
pp. 999 – 1006

Abstract

Read online

Venetoclax and azacitidine combination therapy (VEN+AZA) is a promising novel therapy for elderly or unfit patients with acute myeloid leukemia (AML). Recently, VEN+AZA with subsequent allo-hematopoietic stem cell transplantation has been reported, and human leukocyte antigen-haploidentical peripheral blood stem cell transplantation using posttransplant cyclophosphamide (PTCy-haplo-PBSCT) from related donors appears to be a suitable option. Here, we report two elderly patients with refractory AML harboring an IDH2 mutation, who were successfully treated with VEN+AZA bridged to PTCy-haplo-PBSCT. This report suggests the efficacy and safety of VEN+AZA as a bridging treatment for PTCy-haplo-PBSCT in refractory AML.

Published in Case Reports in Oncology

ISSN: 1662-6575 (Online)
Publisher: Karger Publishers
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.karger.com/cro

About the journal

Abstract

Keywords